NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/04/2024
Back to search
Official data from USPTO
ACERAND THERAPEUTICS A
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
19
Latest update
06/04/2024
Trademark type
Combined
Nice classes
42
Filing date
03/15/2023
Registration date
06/04/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/04/2024
Last transaction
06/04/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
16
Owner location
Hong Kong, HK
Examiner
LIU, PHILIP HUAI-EN
Law office
L90
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the wording "ACERAND THERAPEUTICS" in stylized font, all below the letter "A" comprising of a triangle.
Holders and representatives
Holders
Acerand Therapeutics (Hong Kong) Limited
Representatives
Charles Ho Barron & Young PLLC
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Technological research in the field of developing pharmaceutical products; Scientific research; Chemical research; Pharmaceutical drug development; Product research and development for others; Scientific laboratory services; Development of pharmaceutical preparations and pharmaceuticals for the treatment of cancerinfection diseasesmetabolic diseasesautoimmune diseasescentral nervous system disorderscardiovascular diseases and endocrine diseases; Pharmaceutical drug development services; Scientific research in the nature of conducting clinical trials for others in the field of cancerinfection diseasesmetabolic diseasesautoimmune diseasescentral nervous system disorderscardiovascular diseases and endocrine diseases; Pharmaceutical research and development
Publications
History of USPTO decisions and trademark events.
19 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/04/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/19/2024
PUBO
PUBLISHED FOR OPPOSITION
03/19/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/28/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/28/2024
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
02/15/2024
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
02/09/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/02/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/01/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/31/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/31/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/19/2023
GNRT
NON-FINAL ACTION E-MAILED
12/19/2023
CNRT
NON-FINAL ACTION WRITTEN
12/19/2023
DOCK
ASSIGNED TO EXAMINER
12/12/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
04/05/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/04/2023
NWAP
NEW APPLICATION ENTERED
03/18/2023
Continuous trademark protection
Get notified about every new filing that threatens ACERAND THERAPEUTICS A or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.